Deep Pharma News Today

Deep Pharma Intelligence released a special report “Artificial Intelligence in Drug Discovery: Focus on Oncology (Q2 2021)”, which builds on the previous

Deep Pharma Intelligence released a special 115-page analytical report Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts), which is

Exscientia. The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory and commercial payments that take the potential value of the deal beyond $1.2 billion. Exscientia will also receive royalties on net sales of any marketed drug products resulting from the collaboration. The biotech industry is increasingly using AI to deploy targeted drug molecules to test the efficacy of drugs to tackle illnes...